DE602005022757D1 - Verwendung von endosialinbindenden proteinen zum isolieren endosialinpositiver zellen - Google Patents

Verwendung von endosialinbindenden proteinen zum isolieren endosialinpositiver zellen

Info

Publication number
DE602005022757D1
DE602005022757D1 DE602005022757T DE602005022757T DE602005022757D1 DE 602005022757 D1 DE602005022757 D1 DE 602005022757D1 DE 602005022757 T DE602005022757 T DE 602005022757T DE 602005022757 T DE602005022757 T DE 602005022757T DE 602005022757 D1 DE602005022757 D1 DE 602005022757D1
Authority
DE
Germany
Prior art keywords
cells
proteins
isolating
monoclonal antibodies
endosialinpositive
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
DE602005022757T
Other languages
English (en)
Inventor
Luigi Grasso
Gaurav Deshmukh
Nicholas Nicolaides
Philip Sass
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Morphotek Inc
Original Assignee
Morphotek Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Morphotek Inc filed Critical Morphotek Inc
Publication of DE602005022757D1 publication Critical patent/DE602005022757D1/de
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2851—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56966—Animal cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G01N33/57492—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds localized on the membrane of tumor or cancer cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/475—Assays involving growth factors
    • G01N2333/515—Angiogenesic factors; Angiogenin
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70596—Molecules with a "CD"-designation not provided for elsewhere in G01N2333/705
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/10—Musculoskeletal or connective tissue disorders
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/16—Ophthalmology
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/24—Immunology or allergic disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • Oncology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Organic Chemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Virology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
DE602005022757T 2004-12-03 2005-12-02 Verwendung von endosialinbindenden proteinen zum isolieren endosialinpositiver zellen Active DE602005022757D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US63306004P 2004-12-03 2004-12-03
PCT/US2005/043749 WO2006060719A2 (en) 2004-12-03 2005-12-02 Use of endosialin binding proteins to isolate endosialin positive cells

Publications (1)

Publication Number Publication Date
DE602005022757D1 true DE602005022757D1 (de) 2010-09-16

Family

ID=36565803

Family Applications (1)

Application Number Title Priority Date Filing Date
DE602005022757T Active DE602005022757D1 (de) 2004-12-03 2005-12-02 Verwendung von endosialinbindenden proteinen zum isolieren endosialinpositiver zellen

Country Status (7)

Country Link
US (1) US20060121541A1 (de)
EP (1) EP1819736B1 (de)
AT (1) ATE476449T1 (de)
AU (1) AU2005311660B2 (de)
CA (1) CA2590583A1 (de)
DE (1) DE602005022757D1 (de)
WO (1) WO2006060719A2 (de)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2607455A1 (en) * 2005-04-22 2006-11-02 Morphotek, Inc. Antibodies with immune effector activity and that internalize in endosialin-positive cells
BRPI0809665B8 (pt) 2007-04-05 2021-05-25 Eisai Inc anticorpo monoclonal que se liga especificamente a endosialina
US20100260769A1 (en) * 2009-04-09 2010-10-14 Morphotek, Inc. Endosialin binding molecules
WO2012050883A1 (en) * 2010-09-29 2012-04-19 Morphotek, Inc. Engineered human endosialin-expressing rodents
DE102017125150B4 (de) 2017-10-26 2019-10-10 Epiontis Gmbh Endosialin (CD248) als epigenetischer Marker zur Identifizierung von Immunzellen, insbesondere naïver CD8+ T-Zellen

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20271A (en) * 1858-05-18 Improvement in harvesters
US121541A (en) * 1871-12-05 Improvement in folding plant-stands
US248034A (en) * 1881-10-11 gibbs
US239911A (en) * 1881-04-05 Parasol
US5789650A (en) * 1990-08-29 1998-08-04 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5342757A (en) * 1992-11-13 1994-08-30 Ludwig Institute For Cancer Research Monoclonal antibodies which specifically binds to endosialin, a 165 Kd glycoprotein found on tumor vascular endothelium, and uses thereof
CA2154266A1 (en) * 1993-02-05 1994-08-18 John F. Codington Human carcinoma antigen (hca), hca antibodies, hca immunoassays, methods of imaging and therapy
DK0746613T3 (da) * 1994-03-08 2006-09-25 Sloan Kettering Inst Cancer Rekombinante humaniserede antistoffer mod FB5
DE19541844C1 (de) * 1995-11-09 1997-07-24 Gsf Forschungszentrum Umwelt Verfahren zur Herstellung von menschlichen Antikörpern und deren Verwendung
US6146894A (en) * 1998-04-14 2000-11-14 The Johns Hopkins University Method for generating hypermutable organisms
DE602004030764D1 (de) * 2003-03-04 2011-02-10 Genzyme Corp Endothelzell-spezifische antikörper und ihre verwendung
US6905082B1 (en) * 2003-12-05 2005-06-14 Sheng Li Wu Sprayer device having buffering structure
WO2005086713A2 (en) * 2004-03-04 2005-09-22 Kirin Brewery Co., Ltd. Role of human endothelial precursor cells and vascular pericytes tumor in angiogenesis
CA2607455A1 (en) * 2005-04-22 2006-11-02 Morphotek, Inc. Antibodies with immune effector activity and that internalize in endosialin-positive cells

Also Published As

Publication number Publication date
ATE476449T1 (de) 2010-08-15
AU2005311660A1 (en) 2006-06-08
WO2006060719A3 (en) 2006-11-23
EP1819736B1 (de) 2010-08-04
CA2590583A1 (en) 2006-06-08
AU2005311660B2 (en) 2011-07-07
WO2006060719A2 (en) 2006-06-08
EP1819736A2 (de) 2007-08-22
US20060121541A1 (en) 2006-06-08

Similar Documents

Publication Publication Date Title
CY1117702T1 (el) Πρωτεϊνες δεσμευομενες με αντιγονο ικανες να δεσμευονται με θυμικη στρωματικη λεμφοποιητινη
TR201910213T4 (tr) Disülfürle stabilize edilmiş çok değerlikli antikorlar.
MX360543B (es) Anticuerpos st-2 humanos solubles y ensayos.
BRPI0507433A (pt) anticorpo monoclonal humano isolado ou sua parte de ligação ao antìgeno, polipeptìdeo isolado, composição, ácido nucleico isolado, vetor de expressão, célula hospedeira, kit, e, métodos para tratar doença de c. difficile em um indivìduo e para tratar uma doença ou distúrbio associado a c. difficile em um mamìfero
CA2808482C (en) Methods for the generation of multispecific and multivalent antibodies
MX2010002269A (es) Composiciones y metodos que comprenden proteinas de union para adalimumab.
EP2352523A4 (de) Verbesserte anti-cd19-antikörper
UA99701C2 (ru) Человеческое моноклональное антитело, которое специфически связывается с лигандом-1 запрограммированной гибели клеток (pd-l1)
EA201591407A1 (ru) Антитела, содержащие химерные константные домены
MX2013006428A (es) Proteinas de union a tnf-alfa.
EA201290413A1 (ru) МУТИРОВАННЫЕ Fc АНТИТЕЛ С УСТРАНЕННЫМИ ЭФФЕКТОРНЫМИ ФУНКЦИЯМИ
EA201490825A8 (ru) Tdp-43-специфически связывающие молекулы
EA200970477A1 (ru) Человеческие моноклональные антитела к btla и способы применения
TW200714711A (en) Anti-cd-20 monoclonal antibody
ATE505544T1 (de) Monoklonale antikörper und einzelkettenantikörper fragments gegen das zelloberflächen prostataspezifische membranantigen
RS54113B1 (en) COMPOSITIONS AND PROCEDURES FOR ANTIBODIES ON THE C5 COMPLEMENTARY PROTEIN
NO20084650L (no) Modifiserte humaniserte anti-interleukin-18 antistoffer
EA201890928A1 (ru) Антигенсвязывающие белки, которые активируют лептиновый рецептор
EA200702361A1 (ru) АНТИТЕЛА ПРОТИВ csPCNA ИЗОФОРМЫ И ИХ ПРИМЕНЕНИЕ
EA201101242A1 (ru) Полностью человеческие антитела, специфические для cadm1
MX2022000652A (es) Anticuerpos contra claudina 18 y metodos de tratamiento del cancer.
EA201101516A1 (ru) Антитела, специфические для кадгерина-17
Chen et al. Anti-human CD138 monoclonal antibodies and their bispecific formats: generation and characterization
DE602005022757D1 (de) Verwendung von endosialinbindenden proteinen zum isolieren endosialinpositiver zellen
WO2020223392A3 (en) Cancer associated antibody compositions and methods of use